1. Viral testing of 18 consecutive cases of equine serum hepatitis: A prospective study (2014-2018).
- Author
-
Tomlinson JE, Kapoor A, Kumar A, Tennant BC, Laverack MA, Beard L, Delph K, Davis E, Schott Ii H, Lascola K, Holbrook TC, Johnson P, Taylor SD, McKenzie E, Carter-Arnold J, Setlakwe E, Fultz L, Brakenhoff J, Ruby R, Trivedi S, Van de Walle GR, Renshaw RW, Dubovi EJ, and Divers TJ
- Subjects
- Animals, Female, Flavivirus, Flavivirus Infections complications, Flavivirus Infections virology, Hepacivirus, Hepatitis C complications, Hepatitis C virology, Hepatitis, Viral, Animal blood, Hepatitis, Viral, Animal pathology, Horse Diseases blood, Horse Diseases pathology, Horses, Liver pathology, Liver virology, Male, Parvoviridae Infections complications, Parvoviridae Infections virology, Parvovirus, Prospective Studies, Real-Time Polymerase Chain Reaction veterinary, Theilovirus, Flavivirus Infections veterinary, Hepatitis C veterinary, Hepatitis, Viral, Animal virology, Horse Diseases virology, Parvoviridae Infections veterinary
- Abstract
Background: Three flaviviruses (equine pegivirus [EPgV]; Theiler's disease-associated virus [TDAV]; non-primate hepacivirus [NPHV]) and equine parvovirus (EqPV-H) are present in equine blood products; the TDAV, NPHV, and EqPV-H have been suggested as potential causes of serum hepatitis., Objective: To determine the prevalence of these viruses in horses with equine serum hepatitis., Animals: Eighteen horses diagnosed with serum hepatitis, enrolled from US referral hospitals., Methods: In the prospective case study, liver, serum, or both samples were tested for EPgV, TDAV, NPHV, and EqPV-H by PCR., Results: Both liver tissue and serum were tested for 6 cases, serum only for 8 cases, and liver only for 4 cases. Twelve horses received tetanus antitoxin (TAT) 4-12.7 weeks (median = 8 weeks), 3 horses received commercial equine plasma 6-8.6 weeks, and 3 horses received allogenic stem cells 6.4-7.6 weeks before the onset of hepatic failure. All samples were TDAV negative. Two of 14 serum samples were NPHV-positive. Six of 14 serum samples were EPgV-positive. All liver samples were NPHV-negative and EPgV-negative. EqPV-H was detected in the serum (N = 8), liver (N = 4), or both samples (N = 6) of all 18 cases. The TAT of the same lot number was available for virologic testing in 10 of 12 TAT-associated cases, and all 10 samples were EqPV-H positive., Conclusions and Clinical Importance: We demonstrated EqPV-H in 18 consecutive cases of serum hepatitis. EPgV, TDAV, and NPHV were not consistently present. This information should encourage blood product manufacturers to test for EqPV-H and eliminate EqPV-H-infected horses from their donor herds., (© 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.)
- Published
- 2019
- Full Text
- View/download PDF